TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29747793

Group type: EXPERIMENTAL
Intervention: Experimental interventions reported in RCT abstracts (100%)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Participant eligibility criteria (#3)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Comparison interventions (#6)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Specific objective or hypothesis (#7)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Primary outcome (#8)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Reporting trial results as a summary (#16)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Identification of the study as randomized in the title (#1)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Design of the trial (#2)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Trial setting (#4)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Randomization (#10)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Blinding (#12)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Details about blinding (#13)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Number of participants randomized to each intervention (#14)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Effect size (#17)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Precision of the estimate of the effect (#18)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Adverse effects (#19)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Statistical significance (#25)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Trial registration number (#21)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Name of trial register (#22)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: How the randomization or sequence generation was done (#22)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: How allocations were concealed (#11)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Source of funding for the trials (#23)
Number of subjects: 198
Study: 27015572

Group type: EXPERIMENTAL
Intervention: Subtenon triamcinolone acetonide (TA) injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Topical nepafenac 0.1%
Number of subjects: 48
Study: 25640290

Group type: EXPERIMENTAL
Intervention: Immediate-release tapentadol
Number of subjects: 666

Group type: COMPARATOR
Intervention: Immediate-release oxycodone
Number of subjects: 666
Study: 23551271

Group type: EXPERIMENTAL
Intervention: eTIPs (electronic CBT intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 21209411

Group type: EXPERIMENTAL
Intervention: AFQ056 (mGluR5 antagonist)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AFQ056
Number of subjects: 30

Group type: COMPARATOR
Intervention: AFQ056 and Placebo
Number of subjects: 30
Study: 17848936

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 IU/day, administered four times a day for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 30
Study: 16403776

Group type: EXPERIMENTAL
Intervention: ExGLU (75 g of glucose in 250 ml of water)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ConGLU (glucose after 2 hours of rest)
Number of subjects: 6

Group type: COMPARATOR
Intervention: ExPL (flavored water as placebo control)
Number of subjects: 6
Study: 12608443

Group type: EXPERIMENTAL
Intervention: SRL172 (heat‐killed Mycobacterium vaccae)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10617751

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with mothers during heel lance
Number of subjects: 30
Study: 9437565

Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low electrical dosage relative to seizure threshold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High electrical dosage relative to seizure threshold
Number of subjects: 0
Study: 8267194

Group type: EXPERIMENTAL
Intervention: Low-dose naloxone (0.5 microgram.kg‐1.min‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose naloxone (11.5 micrograms/kg bolus followed by 5 micrograms.kg‐1.min‐1 infusion)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study: 3545282

Group type: EXPERIMENTAL
Intervention: 100 mg danazol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 200 mg danazol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 400 mg danazol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29655497

Group type: EXPERIMENTAL
Intervention: Intraosseous regional administration (IORA) of 500 mg vancomycin into the tibia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Systemic intravenous (IV) administration of 15 mg/kg (maximum of 2 g) vancomycin
Number of subjects: 22
Study: 27553026

Group type: EXPERIMENTAL
Intervention: Wiki-inspired modified nominal group technique (NGT) over 3 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: In-person nominal group technique (NGT) workshop for 1 day
Number of subjects: 56
Study: 26651278

Group type: EXPERIMENTAL
Intervention: Helmetless-tackling intervention (5-minute tackling drill without helmets and shoulder pads, twice per week in preseason and once per week during the season)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (noncontact football skills)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Helmetless-tackling intervention
Number of subjects: 50
Study: 24282209

Group type: EXPERIMENTAL
Intervention: Hypoxic (HYP) group (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Norm (NORM) group (n=8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups (HYP and NORM)
Number of subjects: 17
Study: 20682933

Group type: EXPERIMENTAL
Intervention: 12-week advocacy intervention comprising empowerment and telephone social support
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual community services including child care, health care and promotion, and recreational programs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 12-week advocacy intervention
Number of subjects: 200
Study: 18842995

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Female gender, unemployment, lower positive affect, greater negative affect
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Structural equation modeling approach
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Multiple risk factor interventions
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Behavioral interventions targeting stress and negative affect
Number of subjects: 399
Study: 18853096

Group type: EXPERIMENTAL
Intervention: DDIR with long AV delay (median AV interval 280 ms)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nominal DDDR mode (AV delay 150/120 ms, AV search hysteresis active)
Number of subjects: 61
Study: 15034952

Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin)
Number of subjects: 0
Study: 11332932

Group type: EXPERIMENTAL
Intervention: Bolus gavage feeding with milk (12 ml kg(‐1) d(‐1) increments, 12 meals per day)
Number of subjects: 41
Study: 9784076

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 3198936

Group type: EXPERIMENTAL
Intervention: Live, attenuated H1N1 reassortant vaccine
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Live, attenuated H3N2 reassortant vaccine
Number of subjects: 252

Group type: COMPARATOR
Intervention: Trivalent inactivated virus vaccine
Number of subjects: 252
Study: 30642381

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine collaborative care (TCMCMC) including standard TCM history taking, physical examination, acupuncture (10 sessions of 30 minutes each), and TCM non-pharmacological advice in addition to usual rheumatologic care.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual rheumatologic care.
Number of subjects: 160
Study: 28713486

Group type: EXPERIMENTAL
Intervention: Concurrent aerobic and resistance training (3 times a week for 16 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Concurrent aerobic and resistance training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (physicians' usual diabetes care advice)
Number of subjects: 16
Study: 25934421

Group type: EXPERIMENTAL
Intervention: Sensorimotor orthoses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Shoe only condition
Number of subjects: 10
Study: 24332352

Group type: EXPERIMENTAL
Intervention: Iodixanol 270 with low-tube-voltage (80 kVp or 100 kVp if BMI ≥ 25 kg/m²) and iterative reconstruction (IR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iopromide 370 with conventional tube setting (100 kVp or 120 kVp if BMI ≥ 25 kg/m²) and filtered back projection (FBP)
Number of subjects: 100
Study: 22816557

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 173

Group type: COMPARATOR
Intervention: CNI (cyclosporine or tacrolimus)
Number of subjects: 173

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 173
Study: 20031007

Group type: EXPERIMENTAL
Intervention: Olopatadine (OLO) nasal spray 0.6% (1 or 2 sprays/nostril, b.i.d.)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Olopatadine (OLO) nasal spray 0.6% (1 spray/nostril, b.i.d.)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Olopatadine (OLO) nasal spray 0.6%
Number of subjects: 132
Study: 17916225

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 14732754

Group type: EXPERIMENTAL
Intervention: Acetylcysteine during hemodialysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo) during hemodialysis
Number of subjects: 20
Study: 11677742

Group type: EXPERIMENTAL
Intervention: Virtual reality stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study: 9560030

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 0.1 IU/kg/d, n=16
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 0.2 IU/kg/d, n=20
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no treatment), n=12
Number of subjects: 48
Study: 7882702

Group type: EXPERIMENTAL
Intervention: 2 mg zuclopenthixol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 4 mg zuclopenthixol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 6 mg zuclopenthixol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 4 mg to 20 mg daily zuclopenthixol (flexible dosing)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All dose groups
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 73
Study: 3065661

Group type: EXPERIMENTAL
Intervention: Thymopentin and Hevac B Pasteur vaccine (3 doses of 5 micrograms s.c. each of vaccine at monthly intervals and 12 doses of 50 mg s.c. of thymopentin on alternate days between the first and the second vaccination)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hevac B Pasteur vaccine (3 doses of 5 micrograms s.c. each of vaccine at monthly intervals)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hevac B Pasteur vaccine (3 doses of 10 micrograms s.c. each of vaccine at monthly intervals)
Number of subjects: 40
Study: 29543739

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) program with bimonthly health education attendance, bringing LBC for vaccinations, and on-time annual health checks
Number of subjects: 447

Group type: COMPARATOR
Intervention: Routine health services only
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) program
Number of subjects: 447
Study: 25999335

Group type: EXPERIMENTAL
Intervention: Agomelatine (n = 172)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo (n = 172)
Number of subjects: 344
Study: 24561548

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg b.d. (with dose reduction to 2.5 mg b.d. for certain patients)
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 22690080

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 60
Study: 20695855

Group type: EXPERIMENTAL
Intervention: Suffocant
Number of subjects: 216

Group type: COMPARATOR
Intervention: Malathion
Number of subjects: 216
Study: 18234243

Group type: EXPERIMENTAL
Intervention: Occlusal appliance
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15625256

Group type: EXPERIMENTAL
Intervention: Priming group (rocuronium 0.06 mg x kg(‐1) followed by 0.54 mg x kg(‐1) three minutes later)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bolus group (rocuronium 0.6 mg x kg(‐1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Priming group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bolus group
Number of subjects: 30
Study: 11786451

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 135000

Group type: EXPERIMENTAL
Intervention: Aspirin (75-150 mg daily)
Number of subjects: 135000

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 135000

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 135000

Group type: EXPERIMENTAL
Intervention: Intravenous glycoprotein IIb/IIIa antagonist added to aspirin
Number of subjects: 135000

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 135000
Study: 10468203

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg once daily
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1200 mg twice daily
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1800 mg thrice daily
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Active treatment (combined ALA groups)
Number of subjects: 74
Study: 7618455

Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg, single oral dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg, single oral dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2756910

Group type: EXPERIMENTAL
Intervention: Carbohydrate infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Protein infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mixed meal infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 963410

Group type: EXPERIMENTAL
Intervention: Hydrophilic polymer-coated latex catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncoated latex catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: PVC catheter
Number of subjects: 0
Study: 29903701

Group type: EXPERIMENTAL
Intervention: EHR condition (49/211, 23%)
Number of subjects: 83

Group type: COMPARATOR
Intervention: SAU condition (34/211, 16%)
Number of subjects: 83
Study: 27701428

Group type: EXPERIMENTAL
Intervention: Krill oil (2 g per day for 30 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24628465

Group type: EXPERIMENTAL
Intervention: Natural cigarette claims on cigarette packages
Number of subjects: 0
Study: 23342764

Group type: EXPERIMENTAL
Intervention: 2.4 atm abs breathing 100% oxygen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham (1.3 atm abs breathing air)
Number of subjects: 50
Study: 21280421

Group type: EXPERIMENTAL
Intervention: Experimental stannous-containing sodium fluoride dentifrice
Number of subjects: 28

Group type: COMPARATOR
Intervention: Colgate Total (positive control)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Crest Cavity Protection (negative control)
Number of subjects: 28
Study: 18799080

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) treatment (20 microg-40 microg-60 microg) administered via intravenous infusion for 3 consecutive days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) treatment
Number of subjects: 50
Study: 15708696

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1301

Group type: COMPARATOR
Intervention: No diabetes mellitus
Number of subjects: 1301
Study: 14516802

Group type: EXPERIMENTAL
Intervention: Atropine treatment
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Atropine treatment followed by plano lens for sound eye
Number of subjects: 195

Group type: COMPARATOR
Intervention: Atropine treatment alone
Number of subjects: 195

Group type: COMPARATOR
Intervention: Atropine treatment with plano lens
Number of subjects: 195
Study: 10656435

Group type: EXPERIMENTAL
Intervention: Exisulind 400 mg p.o. twice a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exisulind 300 mg p.o. twice a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exisulind 200 mg p.o. twice a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exisulind (all doses)
Number of subjects: 18
Study: 9411480

Group type: EXPERIMENTAL
Intervention: Prone position biopsy (n = 51; using TRC‐Mammotest, Sweden)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sitting position biopsy (n = 52; using Stereotix 2, General Electric Medical Systems, Milwaukee, Wisconsin, USA)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Prone position biopsy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sitting position biopsy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 103
Study: 9582639

Group type: EXPERIMENTAL
Intervention: Fixed appliance therapy (non-extraction)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fixed appliance therapy (extraction)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fixed appliance therapy (both groups)
Number of subjects: 35
Study: 3777409

Group type: EXPERIMENTAL
Intervention: Nalbuphine 2.5 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nalbuphine 5 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nalbuphine 10 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nalbuphine 20 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nalbuphine 5 mg after fentanyl
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nalbuphine (all doses) after fentanyl
Number of subjects: 80
Study: 29183872

Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin challenge in lean men
Number of subjects: 75

Group type: COMPARATOR
Intervention: Endotoxin exposure (measured by serum levels of lipopolysaccharide-binding protein)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Multivariate analysis of serum IL-6
Number of subjects: 75
Study: 27235530

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of parathyroid hormone (PTH) for six weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 29
Study: 24966227

Group type: EXPERIMENTAL
Intervention: Perturbation training (24 unannounced repeated slips)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (1 slip)
Number of subjects: 212
Study: 23083434

Group type: EXPERIMENTAL
Intervention: Cementless press-fit socket with additional screw fixation (group A, n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cementless press-fit socket without additional screw fixation (group B, n = 18)
Number of subjects: 37
Study: 20528001

Group type: EXPERIMENTAL
Intervention: AZD0837 intravenous infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18829786

Group type: EXPERIMENTAL
Intervention: Biannual fat-oriented dietary counseling (intervention group, n = 540)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Control group (n = 522)
Number of subjects: 541
Study: 16076821

Group type: EXPERIMENTAL
Intervention: ALPHA form intervention
Number of subjects: 227

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 227
Study: 11336590

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0
Study: 10197189

Group type: EXPERIMENTAL
Intervention: Alcohol (breath‐alcohol level of 0.1%)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8311312

Group type: EXPERIMENTAL
Intervention: Desflurane (1 MAC) and nitrous oxide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Halothane (1 MAC) and nitrous oxide
Number of subjects: 45
Study: 3046820

Group type: EXPERIMENTAL
Intervention: 100 mg mixed gangliosides (Cronassial) every weekday intramuscularly for 3-4 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg mixed gangliosides (Cronassial) after 13-19 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg mixed gangliosides (Cronassial) after greater than 20 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo injections for 3 months
Number of subjects: 30
Study: 1540790

Group type: EXPERIMENTAL
Intervention: Thalassaemia minor cases
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 352763

Group type: EXPERIMENTAL
Intervention: 1% erythromycin base applied once a day for 10 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1.19% clindamycin phosphate (1% clindamycin base) applied with the same procedure
Number of subjects: 33

Group type: COMPARATOR
Intervention: unspecific cream vehicle without active agent
Number of subjects: 33

Group type: COMPARATOR
Intervention: unspecific vehicle for clindamycin treatment
Number of subjects: 33
Study: 31500787

Group type: EXPERIMENTAL
Intervention: Recurrent Liver Cancer Score (RLCS) developed in the training set
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Validation set of RLCS
Number of subjects: 1125
Study: 28429905

Group type: EXPERIMENTAL
Intervention: 25,000 IU/4-weekly cholecalciferol (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50,000 IU/4-weekly cholecalciferol (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both doses (25,000 IU and 50,000 IU)
Number of subjects: 90